Is Seladelpar effective in reversing liver fibrosis?

Seladelpar is a selective peroxisome proliferator-activated receptor delta (PPARdelta) agonist. In recent years, it has attracted much attention in the field of treatment of cholestatic liver disease and metabolic liver disease. It has the potential to improve liver metabolic disorders and reduce liver inflammation by regulating lipid metabolism and anti-inflammatory mechanisms. Regarding the complex pathological process of liver fibrosis, the mechanism of action and clinical research results of Siladepa show a certain possibility of reversal.

Liver fibrosis is the excessive deposition of collagen caused by the activation of hepatic stellate cells after long-term injury to the liver, leading to changes in liver tissue structure and decline in function. Siladepa promotes the oxidative metabolism of fatty acids, reduces liver fat accumulation, and relieves liver stress from the source by activating the PPAR delta receptor. At the same time, it can also inhibit the release of pro-inflammatory cytokines, reduce liver inflammation, and block key links in the progression of fibrosis.

Multiple clinical trials have shown that Siladepa has a significant effect in improving liver function indicators and inflammatory responses in patients with non-alcoholic steatohepatitis (NASH), and some patients have also improved the degree of liver fibrosis to varying degrees. Although the current evidence for direct reversal of liver fibrosis is limited, its anti-inflammatory and metabolic regulatory effects provide a good basis for the alleviation of liver fibrosis.

Overall, as aPPARδ agonist, Siladepa has the potential to reduce the development of liver fibrosis through multiple mechanisms and even promote a certain degree of reversal. With the accumulation of more large-scale clinical data in the future, Siladepa is expected to become an important drug choice for the treatment of liver fibrosis, bringing new treatment hope to patients with liver disease.

Reference materials:https://www.drugs.com

xa0